Bloodless chimeric antigen receptor (CAR) T-cell therapy in Jehovah’s Witnesses

Click to increase image sizeClick to decrease image size

Disclosure statement

PAR receives research support from Kite/Gilead, Novartis, Celgene/BMS, MorphoSys, Calibr, has served on advisory boards or provided consulting for Bayer, Novartis, Kite/Gilead, Karyopharm, Verastem, BeiGene, Takeda, Celgene/BMS, and on speakers bureau for Bayer, and Kite/Gilead

MW reports no relevant conflicts of interest.

JMC reports no relevant conflicts of interest.

JMG has served on a speakers bureau for Sanofi Genzyme and BMS and has participated on advisory boards for Celgene

AJJ reports consulting and advisory boards for AbbVie, Amgen, BMS, GSK, Janssen, and Karyopharm Therapeutics Inc.

JPK receives research support from Merck, Verastem, and iTeos, has served on a speakers bureau for Kite/Gilead, and has served on advisory boards for Verastem, Seattle Genetics, MorphoSys, and Karyopharm

SK reports no relevant conflicts of interest.

HL received research support from BMS and Karyopharm, has served on advisory board meeting for Agios.

SMS received research support from FortySeven, TG Therapeutics, Pharmacyclics, Acerta, Celgene, Novartis, Genentech/Roche, Epizyme, has served as a consultant for Janssen, Bristol Myers Squibb, Bantam, Karyopharm, Genentech, Celgene, Bayer, and TG Therapeutics.

MRB receives research support from Kite/Gilead, Novartis, Arcellx, CRISPR Therapeutics, has served on advisory boards for Kite/Gilead, Novartis, Arcellx, CRISPR Therapeutics, Autolus, Juno, Takeda, and Celgene, and on speakers bureaus for BMS, Incyte, Sanofi, and Kite/Gilead.